NK - NantKwest is up in pre-market as Piper Sandler remains bullish on stock

NantKwest (NK) has climbed 36.2% in premarket trading as Piper Sandler reiterates its overweight rating on the company after yesterday’s announcement of the early interim results yesterday for survival rates in metastatic pancreatic cancer trials.With a primary endpoint of overall survival, the single-arm Phase 2 study (QUILT 88, Cohort C) initiated in October 2020 has demonstrated based on the early data that 15 out of 18 (83%) of patients enrolled with second-line or greater pancreatic cancer has remained alive to date.Noting that ‘the data are very immature with only 6 patients beyond 60 days of follow-up,’ the analyst Joseph M. Catanzaro acknowledges the inability to draw many conclusions based on the results.However, ‘we're very encouraged by the rate of early enrollment’ writes Catanzaro expecting that the cohort C with longer follow-up to provide ‘a sizable and meaningful dataset in 2021.’It could confirm the ‘potential of the PD-L1 t-haNK regimen in the lateline

For further details see:

NantKwest is up in pre-market as Piper Sandler remains bullish on stock